ARTA
PCRX icon

A.R.T. Advisors’s Pacira BioSciences PCRX Stock Holding History

A.R.T. Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,526
Closed -$401K – 1621
2019
Q3 		$401K Sell
10,526
-2,000
-16% -$79.8K 0.02% 943
2019
Q2 		$545K Buy
12,526
+2,100
+20% +$89.2K 0.03% 715
2019
Q1 		$397K Buy
+10,426
New +$407K 0.02% 831
2018
Q1 		– Sell
-8,300
Closed -$378K – 1698
2017
Q4 		$378K Buy
+8,300
New +$329K 0.02% 999
2017
Q2 		– Sell
-48,200
Closed -$2.2M – 1645
2017
Q1 		$2.2M Sell
48,200
-8,900
-16% -$385K 0.1% 284
2016
Q4 		$1.84M Buy
57,100
+41,000
+255% +$1.37M 0.11% 294
2016
Q3 		$550K Sell
16,100
-64,005
-80% -$2.51M 0.18% 177
2016
Q2 		$2.7M Buy
+80,105
New +$3.94M 0.13% 220
2016
Q1 		– Sell
-33,407
Closed -$2.56M – 1583
2015
Q4 		$2.56M Sell
33,407
-10,727
-24% -$607K 0.12% 218
2015
Q3 		$1.81M Buy
44,134
+34,722
+369% +$2.13M 0.07% 409
2015
Q2 		$665K Sell
9,412
-26,219
-74% -$2.06M 0.02% 887
2015
Q1 		$3.17M Sell
35,631
-24,068
-40% -$2.44M 0.11% 250
2014
Q4 		$5.29M Buy
59,699
+25,729
+76% +$2.43M 0.2% 119
2014
Q3 		$3.29M Buy
33,970
+22,505
+196% +$2.19M 0.15% 188
2014
Q2 		$1.05M Sell
11,465
-23,238
-67% -$1.77M 0.05% 488
2014
Q1 		$2.43M Buy
34,703
+22,628
+187% +$1.54M 0.13% 206
2013
Q4 		$694K Sell
12,075
-29,419
-71% -$1.55M 0.04% 641
2013
Q3 		$2M Sell
41,494
-9,235
-18% -$337K 0.11% 269
2013
Q2 		$1.47M Buy
+50,729
New +$1.47M 0.05% 488

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

A.R.T. Advisors's PCRX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 10,526 shares — an estimated $401K sold.

A.R.T. Advisors first reported a position in PCRX in Q2 2013 and held it in 19 quarters. The position peaked at $5.29M in Q4 2014. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • A.R.T. Advisors reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 10,526 Pacira BioSciences shares in Q4 2019, an estimated $401K.
  • A.R.T. Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 19 quarters.
  • A.R.T. Advisors's Pacira BioSciences position peaked at $5.29M in Q4 2014.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.